Nobody knows the true scale and severity of this outbreak
In the eastern Democratic Republic of Congo, a rare strain of Ebola called Bundibugyo is spreading across provinces and into neighboring Uganda faster than health systems can measure it — a condition more unsettling, in some ways, than the confirmed numbers themselves. Officials in Bunia have acknowledged what epidemics often reveal before anything else: that the gap between what is known and what is true can be the most dangerous territory of all. With experimental treatments arriving and laboratories expanding, the response is accelerating, but the virus, indifferent to timelines, continues to move through communities and into the hospitals meant to stop it.
- Suspected case counts swung from over a thousand to 349 in just four days, exposing how little grip health officials have on the outbreak's true shape.
- Healthcare workers in Bunia are among the newly confirmed cases, signaling that the facilities designed to contain the virus are themselves becoming sites of transmission.
- Testing backlogs are leaving hundreds of samples unanalyzed while new suspected cases arrive daily, creating a dangerous lag between reality and the numbers being reported.
- Doctors Without Borders has warned that no Ebola outbreak has ever recorded so many cases so quickly after declaration — a benchmark that underscores the response's urgency.
- Three experimental therapeutics, including two monoclonal antibodies and Gilead's remdesivir, are being fast-tracked into clinical trials, with U.S. CDC support, among confirmed cases in real time.
- As international aid and laboratory capacity grow, the outbreak continues to outpace the response, leaving responders navigating decisions inside a fog of incomplete information.
On a Saturday in Bunia, health officials announced 260 confirmed Ebola cases — but the number that unsettled the room was the one no one could provide. The true scale of the outbreak, caused by the rare Bundibugyo strain, remained unknown.
The virus had spread across more than a dozen health zones in three provinces, with nine cases recorded in Uganda, including one death. The volatility of the data told its own story: suspected case counts had lurched from 1,077 on Tuesday to 349 by Thursday as laboratories worked through backlogs, separating real infections from false alarms. Doctors Without Borders deputy operations director Alan Gonzalez offered a stark assessment — no Ebola outbreak had ever produced so many cases so quickly after being declared.
Health Minister Roger Kamba pointed to expanded testing as a sign of progress. His ministry had conducted over 900 tests and built capacity for 200 to 300 samples daily. But hundreds of samples still waited in queues, and new suspected cases kept arriving. The infrastructure was growing; the virus was growing faster.
More troubling still, five of the 84 newly confirmed cases were healthcare workers in Bunia itself — a sign that infection control inside medical facilities was failing, and that the people trying to contain the outbreak were becoming part of it.
Kamba announced that the U.S. CDC would support trials of an experimental antibody treatment, with initial doses expected soon. The WHO had identified three candidate drugs — monoclonal antibodies MBP134 and Maftivimab, and Gilead's antiviral remdesivir — for clinical evaluation. None were proven cures. All were being tested in real time on a population with no established treatment options.
As the press conference ended, the essential truth remained what Gonzalez had said plainly: the outbreak's full scale and severity were still unknown. The response was mobilizing, but the virus was moving through a landscape that no one could yet see whole.
In Bunia, a city in the eastern Democratic Republic of Congo, health officials gathered on Saturday to announce a grim milestone: 260 confirmed cases of Ebola. But the number that haunted the room was the one they couldn't pin down. Nobody, they admitted, actually knew how many people had the virus.
The outbreak, caused by a rare variant called Bundibugyo, had spread across more than a dozen health zones spanning three provinces. Uganda had recorded nine cases, including one death. What made this particular outbreak strange and frightening was its speed. In the span of just four days, suspected case counts had swung wildly—from a peak of 1,077 on Tuesday down to 349 by Thursday—as laboratories worked through the backlog of samples and separated confirmed infections from false alarms. The volatility itself was a sign of how little grip officials had on the situation.
Health Minister Roger Kamba stood before reporters and acknowledged the core problem: testing capacity had been the bottleneck. His ministry had conducted more than 900 tests and expanded laboratory infrastructure to handle 200 to 300 samples daily. It sounded like progress. It wasn't enough. Hundreds of samples still sat in queues waiting for analysis. New suspected cases arrived every day. Alan Gonzalez, deputy director of operations for Doctors Without Borders, put it plainly: the epidemic was spreading faster than responders could assess it. "Never before has an Ebola outbreak recorded so many cases so soon after its declaration," he said.
The virus was finding its way into hospitals. Among 84 newly confirmed cases reported late the previous week were five healthcare workers in Bunia itself. That detail carried weight. It meant the disease wasn't just moving through the general population—it was breaching the facilities meant to contain it, infecting the people trying to stop it. Infection control measures in medical facilities, it seemed, were not holding.
Kamba announced that the United States Centers for Disease Control and Prevention had agreed to support trials of an experimental antibody treatment. The therapy had shown promise in animal studies and early human testing. Initial doses were expected to arrive soon. The World Health Organization's independent advisors had already identified three candidate drugs worth pursuing: two monoclonal antibodies called MBP134 and Maftivimab, and an antiviral from Gilead Sciences called remdesivir. These were not cures. They were possibilities being tested in real time on a population facing a virus that had no proven treatment.
What remained true as Saturday's press conference ended was what Gonzalez had stated plainly: the true scale and severity of the outbreak remained unknown. Testing was expanding. Laboratories were working. International support was arriving. But the virus was moving faster than any of it, and the people trying to stop it were still operating in a fog of incomplete information, racing to understand an outbreak they could not yet see whole.
Citações Notáveis
Nobody knows the true scale and severity of this outbreak. Never before has an Ebola outbreak recorded so many cases so soon after its declaration.— Alan Gonzalez, deputy director of operations, Doctors Without Borders
The experimental antibody treatment is very promising and will help determine its efficacy through a mid-stage trial supported by U.S. health authorities.— Health Minister Roger Kamba
A Conversa do Hearth Outra perspectiva sobre a história
Why does the number keep changing so dramatically—from over a thousand suspected cases to 349 in just four days?
Because they're testing samples that have been sitting in a queue. Some turn out to be Ebola, most don't. The wild swings aren't the outbreak getting better or worse—they're the testing catching up to reality, slowly.
So the real number could still be much higher than 260?
Almost certainly. There are hundreds of samples waiting to be tested. And new suspected cases are being reported every single day. The 260 is just what they've confirmed so far.
What worries you most about healthcare workers getting infected?
It means the virus is getting into the places where people go to be treated. If infection control is breaking down in hospitals, the outbreak doesn't just spread—it accelerates. Sick people bring more sick people.
Is the experimental treatment a real option, or just hope?
It's somewhere between. It's shown promise in labs and early tests. But they're starting a clinical trial now, on confirmed cases, in the middle of an outbreak they don't fully understand. It's the best tool they have, but it's untested at this scale.
Why does it matter that this is the Bundibugyo strain specifically?
It's rare. Most Ebola outbreaks are caused by other strains. Bundibugyo behaves differently, spreads differently. The medical playbook they've used before might not work the same way here.
What happens next?
They keep testing. They wait for the experimental drugs to arrive. They try to get infection control right in hospitals. And they hope the true number stops climbing before it becomes something they truly cannot contain.